Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, with a satisfactory Voluntary Action Indicated (VAI) classification. The inspection was conducted from April 13, 2026, to April 17, 2026.

Nilesh Gupta, Managing Director, Lupin, said, "We are pleased to receive the EIR with a VAI classification from the U.S. FDA for our Somerset facility. This outcome reflects our unwavering commitment to quality, compliance, and operational excellence, and reinforces our dedication to manufacturing highquality medicines that patients around the world can trust."

Shares of Lupin Limited was last trading in BSE at Rs. 2476.10 as compared to the previous close of Rs. 2398.70. The total number of shares traded during the day was 26074 in over 3730 trades.

The stock hit an intraday high of Rs. 2480.00 and intraday low of 2410.70. The net turnover during the day was Rs. 64058213.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA EIR SomersetFacility VAIClassification